The Clinical Burden of Hypereosinophilic Syndrome in a Large United States Cohort

This is the authors' abstract. We don't add key points for this paper.

BACKGROUND: There are limited real-world analyses of patients with hypereosinophilic syndrome (HES) in the United States. OBJECTIVE: To describe and compare treatment patterns and disease burden between patients with diagnosed or predicted HES and those without HES with elevated blood eosinophil count (BEC). METHODS: test for categorical variables. RESULTS: The study included 212 patients in group 1, 8089 in group 2, and 132,945 in group 3. Approximately 62.3% of group 1 patients received 1 or more HES-related treatment, with corticosteroids being the most common (59.0%). The most common disease manifestations were those related to the upper airway/pulmonary (61.8%), constitutional (46.2%), dermatologic (35.8%), and gastrointestinal systems (34.4%). Among patients in group 1, 22.2%, 97.2%, and 25.9% had 1 or more inpatient, outpatient, and emergency department visit, respectively. Compared with group 3, groups 1 and 2 had more corticosteroid use and health care resource utilization (all P < .05). CONCLUSIONS: Patients with HES had a substantial clinical and health care resource utilization burden versus those without HES with elevated BEC.